Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reactions Weekly
Published in: Reactions Weekly 1/2024

01-03-2024 | Bimatoprost | Case report

Bimatoprost

Bilateral cystoid macular oedema

Published in: Reactions Weekly | Issue 1/2024

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
…
Literature
Patel SH, et al. BILATERAL CYSTOID MACULAR EDEMA AFTER BIMATOPROST IMPLANTS. Retinal Cases and Brief Reports 18 : 218-220, No. 2, Mar 2024. Available from: URL: https://dx.doi.org/10.1097/ICB.0000000000001346 [Summarised from an abstract]
Metadata
Title
Bimatoprost
Bilateral cystoid macular oedema
Publication date
01-03-2024
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-54397-z

Other articles of this Issue 1/2024

Reactions Weekly 1/2024 Go to the issue

Case report

Factor-VIII-inhibitor-bypassing-fraction

Case report

Sirolimus/Tacrolimus

Case report

Multiple drugs

Case report

Tocilizumab

Case report

Multiple drugs

Case report

Cisplatin/fluorouracil/pembrolizumab